Science and Research

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study

RATIONALE: The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. OBJECTIVES: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age, sex and comorbidity matched population. METHODS: An international multicenter audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death. MEASUREMENTS AND MAIN RESULTS: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and co-morbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 2.27, 1.39-3.71). CONCLUSIONS: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Drake, T. M.
  • Docherty, A. B.
  • Harrison, E. M.
  • Quint, J. K.
  • Adamali, H.
  • Agnew, S.
  • Babu, S.
  • Barber, C. M.
  • Barratt, S.
  • Bendstrup, E.
  • Bianchi, S.
  • Castillo Villegas, D.
  • Chaudhuri, N.
  • Chua, F.
  • Coker, R.
  • Chang, W.
  • Crawshaw, A.
  • Crowley, L. E.
  • Dosanjh, D.
  • Fiddler, C. A.
  • Forrest, I. A.
  • George, P. M.
  • Gibbons, M. A.
  • Groom, K.
  • Haney, S.
  • Hart, S. P.
  • Heiden, E.
  • Henry, M.
  • Ho, L. P.
  • Hoyles, R. K.
  • Hutchinson, J.
  • Hurley, K.
  • Jones, M. G.
  • Jones, S.
  • Kokosi, M.
  • Kreuter, M.
  • Mackay, L. S.
  • Mahendran, S.
  • Margaritopoulos, G.
  • Molina-Molina, M.
  • Molyneaux, P. L.
  • O'Brien, A.
  • O'Reilly, K.
  • Packham, A.
  • Parfrey, H.
  • Poletti, V.
  • Porter, J. C.
  • Renzoni, E.
  • Rivera-Ortega, P.
  • Russell, A. M.
  • Saini, G.
  • Spencer, L. G.
  • Stella, G. M.
  • Stone, H.
  • Sturney, S.
  • Thickett, D.
  • Thillai, M.
  • Wallis, T.
  • Ward, K.
  • Wells, A. U.
  • West, A.
  • Wickremasinghe, M.
  • Woodhead, F.
  • Hearson, G.
  • Howard, L.
  • Baillie, J. K.
  • Openshaw, P. J. M.
  • Semple, M. G.
  • Stewart, I.
  • Jenkins, R. G.

Keywords

  • COVID-19, IPF, ILD, Obesity, Lung Function, hospitalisation
Publication details
DOI: 10.1164/rccm.202007-2794OC
Journal: Am J Respir Crit Care Med
Work Type: Original
Location: TLRC
Disease Area: PALI, DPLD
Partner / Member: Thorax
Access-Number: 33007173

DZL Engagements

chevron-down